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N Outcomes at 3 years
Progression P PFS P OS P
Bad Risk
Cytogenetics/
Blasts BM >4%
or PB blast >0%
No / No 77 35% Ref. 44% Ref. 46% Ref.
Yes / No 31 39% 0.1 28% 0.02 30% 0.01
No / Yes 117 50% 0.002 21% <0.001 23% <0.001
Yes / Yes 110 57% <0.001 14% <0.001 16% <0.001
Figure.
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Background: Patients with advanced AML, ie, those not in
ﬁrst (CR1) or second complete remission (CR2) have poor
outcome and are considered poor transplant candidates. The
purpose of this study was to identify a subgroup of patients
with active disease at the time of transplant that beneﬁts
from allogeneic transplantation.
Patients and Methods: Between 2005 and 2013, 782 pa-
tients underwent allogeneic transplant from a fully matched
(10/10) related or unrelated donor at our center. Of these 361
patients with advanced disease, deﬁned as patient not in CR1
or CR2, were included in this analysis. Cox proportional
hazards regression analysis was used for univariate and
multivariate analysis to predict overall survival. Variables
considered in the analysis were age, sex, SWOG cytogenetics
risk group, BM and PB blast%, regimen intensity (myelo-
ablative v/s reduced intensity) and type of AML (de novo,
secondary to MDS or MPD or therapy related AML).
Results: At a median follow up of 26 months in the surviving
patients, OS, PFS, NRM and relapse rate were 26%, 24%, 23%
and 48%, respectively. In a univariate analysis poor risk
cytogenetics (P<0.001) and bone marrow blasts >4%
(P 0.006) or any blasts in peripheral blood (P<.001) indicatedadverse outcome for OS. When poor risk cytogenetics and
peripheral and/or bone marrow blasts were considered
simultaneously (Table 1, ﬁg 1), signiﬁcantly superior survival
was observed in patients with less than 5% BM blasts without
any circulating blast and good or intermediate risk
cytogenetics. This impact was also seen for PFS and disease
progression. At 3 years PFS and OS were 44% and 46% in
this subgroup.
Conclusion: Patients with low blast counts in the absence of
poor-risk cytogenetics should be considered for transplant,
even if they are not in remission.438
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Cell requests for allogeneic bone marrow grafts are deﬁned
by the amount of total nucleated cells (TNC) according to
body weight of the recipient. However, outcome of bone
marrow transplantation signiﬁcantly depends on the
amount of infused CD34+ stem and progenitor cells repre-
senting around 0.5 to 1.5% of TNC. So far, TNC as well as the
CD34+ progenitor yield of marrow harvests cannot be pre-
dicted.We retrospectively analyzed donor variables, TNC and
progenitor yields of 1275 marrow collections (860 male and
415 female) that have been performed in our collection
center - all of those with same experienced staff of physi-
cians. Maximum amount of bone marrow that was allowed
to harvest was 20 ml/kg donor weight but limited to a
maximum of 1500 ml. The mean TNC count in the ﬁnal
product was analyzed with 16.6 TNC/nl (5.9-46.6) corre-
sponding to 5.6  4.3 TNC/kg body weight of the recipient.
The mean CD34+cell concentration in the graft was
measured with 111/ml (11-674) corresponding to 4.3  3.9
CD34+cells/kg. We ﬁtted linear regression model for TNC
adjusted for harvest volume and recipient weight to identify
inﬂuential donor variables. Model selection was performed
by backward elimination (BE) with the Bayesian information
criterion (BIC). Peripheral blood leucocytes of the donor
(WBC) before harvest, constitutional donor variables (weight
and height), age, platelet count (PLT), smoking status and
mononuclear cell count (MNC) before harvest could be
identiﬁed as predictive donor parameters for TNC-concen-
tration in the bone marrow product e ordered in descending
mode by Wald-test statistic. Interestingly, the inﬂuence of
donor parameters for CD34+ progenitor cell concentration in
the marrow was different from TNC. Constitutional param-
eters of the donor were identiﬁed to be most important for
CD34+ cell concentration in the marrow product followed by
WBC, age and PLT, whereas smoking status and MNC did not
inﬂuence CD34+ cell harvest. With sex speciﬁc centered
parameters donor sex was only inﬂuential - for both TNC as
well as CD34+ cells - through the constitutional parameters
weight and height. No signiﬁcant interactions could be found
between harvested volume and the identiﬁed donor pa-
rameters. Taking also the recipient weight into account we
propose a model that allows identiﬁcation of risk constella-
tions for achieving the designated amount of TNC as well as
